GlassScriptPhysician profile
Erica Ford
NPI 1497137780
$3,764.99
in general payments reported to CMS, 2019-2025
35 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,181 · 2022: $659 · 2023: $76.06 · 2024: $678 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $452.58 | 2022-2025 | |
| Abbvie INC. | $355.91 | 2021-2022 | |
| Boston Scientific Corporation | $264.53 | 2024-2025 | Resonate El Icd Vr, Latitude Communicator Power Supply, Bodyguardian |
| Amgen INC. | $229.54 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $212.48 | 2024-2025 | Lifevest |
| Lilly USA, LLC | $208.70 | 2021-2022 | |
| Pfizer INC. | $205.47 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $195.84 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.65 | 2022-2025 | Jardiance |
| Esperion Therapeutics, INC. | $158.59 | 2021 | |
| Novo Nordisk INC | $135.94 | 2021-2025 | Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $127.09 | 2022-2024 | |
| Medtronic, INC. | $109.95 | 2022 | |
| Abbott Laboratories | $102.58 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $97.36 | 2025 | Eliquis, Camzyos |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $85.42 | 2021-2022 | |
| Dexcom, INC. | $80.78 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $71.05 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $56.72 | 2022 | |
| Fresenius USA Marketing, INC. | $52.79 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $49.11 | 2024 | Jynarque |
| Scpharmaceuticals INC. | $47.00 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.56 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.98 | 2022 | |
| Ani Pharmaceuticals, INC. | $27.43 | 2024 | Purified Cortrophin Gel |
| Ardelyx, INC. | $26.88 | 2024 | Ibsrela |
| Exact Sciences Corporation | $23.49 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $23.33 | 2021 | |
| Evoke Pharma, INC. | $22.75 | 2022 | |
| Astellas Pharma US INC | $18.66 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.04 | 2025 | Onpattro |
| Philips North America LLC | $14.45 | 2025 | Extended Holter |
| Smith+Nephew, INC. | $13.92 | 2021 | |
| Lifescan, INC. | $12.49 | 2022 | |
| Xeris Pharmaceuticals, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.